SANGAMO THERAPEUTICS, INC. Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax
SANGAMO THERAPEUTICS, INC. (SGMOQ) reported Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax of -$53.13 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest · last filed 2022-11-03
- SANGAMO THERAPEUTICS, INC. income (loss), including portion attributable to noncontrolling interest, before tax for the quarter ending 2022-09-30 was -$53.13M.
- SANGAMO THERAPEUTICS, INC. income (loss), including portion attributable to noncontrolling interest, before tax for the quarter ending 2022-06-30 was -$43.09M.
- SANGAMO THERAPEUTICS, INC. income (loss), including portion attributable to noncontrolling interest, before tax for the quarter ending 2022-03-31 was -$43.92M.
- SANGAMO THERAPEUTICS, INC. income (loss), including portion attributable to noncontrolling interest, before tax for the quarter ending 2021-09-30 was -$47.60M.
| Period end | Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax 3 month | Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax 6 month | Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax 9 month |
|---|---|---|---|
| 2022-09-30 | -$53.13M 10-Q · filed 2022-11-03 | -$96.22M derived: sum of 2 quarters · filed 2022-11-03 | -$140.13M 10-Q · filed 2022-11-03 |
| 2022-06-30 | -$43.09M 10-Q · filed 2022-08-04 | -$87.01M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | -$43.92M 10-Q · filed 2022-05-05 | ||
| 2021-09-30 | -$47.60M 10-Q · filed 2022-11-03 | -$94.75M derived: sum of 2 quarters · filed 2022-11-03 | -$140.43M 10-Q · filed 2022-11-03 |
| 2021-06-30 | -$47.15M 10-Q · filed 2022-08-04 | -$92.83M 10-Q · filed 2022-08-04 | |
| 2021-03-31 | -$45.68M 10-Q · filed 2022-05-05 | ||
| 2020-09-30 | -$1.27M 10-Q · filed 2021-11-04 | -$37.24M derived: sum of 2 quarters · filed 2021-11-04 | -$80.21M 10-Q · filed 2021-11-04 |
| 2020-06-30 | -$35.97M 10-Q · filed 2021-08-05 | -$78.94M 10-Q · filed 2021-08-05 | |
| 2020-03-31 | -$42.97M 10-Q · filed 2021-05-04 | ||
| 2019-09-30 | -$27.36M 10-Q · filed 2020-11-04 | -$99.92M 10-Q · filed 2020-11-04 |